NasdaqGS:MRNABiotechs
Moderna (MRNA) Stock Falls As Pipeline Delays Cloud Revenue Growth
Moderna came into this earnings print as a high‑expectation growth story with a volatile stock to match. After the release, the share price dropped about 5% to US$54.82, which indicates that the market focused on the pain rather than the progress.
The headline is clear. Q2 2026 revenue was US$145m, while the company reported a net loss of US$782m and highlighted cash and investments of US$6.9b. The core question for investors is whether that widening loss profile outweighs the comfort of a...